CSL Vifor and Travere Therapeutics, Inc., today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy (IgAN) ...
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT TrialSAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- , (Nasdaq: TVTX) ...
For many women, the path to recovery from addiction feels isolating and overwhelming. Imagine juggling childcare, work, and the constant internal struggle. A new segment of Empowered with Meg Ryan ...